Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB

Federated Hermes Inc. bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 422,938 shares of the company’s stock, valued at approximately $12,972,000. Federated Hermes Inc. owned 0.07% of Genmab A/S at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares in the last quarter. CWM LLC boosted its stake in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. AlphaCore Capital LLC acquired a new stake in Genmab A/S during the 2nd quarter valued at $44,000. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in Genmab A/S by 136.3% in the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Trading Down 2.2%

Shares of GMAB opened at $32.63 on Friday. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $35.43. The firm has a market cap of $20.96 billion, a price-to-earnings ratio of 13.89, a PEG ratio of 19.53 and a beta of 0.90. The stock has a 50 day moving average of $32.47 and a 200-day moving average of $29.11.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. On average, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

Analyst Ratings Changes

Several brokerages have recently weighed in on GMAB. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a research note on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Truist Financial restated a “buy” rating and set a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Finally, Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.25.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.